To determine the rate of re-treatment in patients who receive a full course of teprotumumab therapy for thyroid eye disease (TED) and drivers of re-treatment. Multicenter retrospective study. All patients who received a full course of treatment and had available data at 1 year after initial treatment were included. Charts were reviewed for the following information: age, sex, months since diagnosis of TED, smoking status, and prior treatments. Further, the clinical activity score (CAS), proptosis, and the Gorman diplopia score were reviewed at baseline, at the end of the first course, and at baseline for the second course in those who received it. A logistic regression model was created to review the drivers of re-treatment. Rate of re-treatment and the drivers of re-treatment. One hundred nineteen patients were included from 3 centers across the United States. The overall re-treatment rate was 24% (29/119). No difference was found among the 3 sites ( = 0.6). In univariable analyses, at baseline, no difference was found in proptosis ( = 0.07), diplopia score ( = 0.4), or duration of TED ( = 0.4) between patients who were re-treated and those not re-treated. From the re-treated group, 82% showed a significant proptosis response (≥ 2-mm reduction from baseline) after the initial course, whereas 68% of patients who were not re-treated showed a clinically significant proptosis response ( = 0.16). The mean ± standard deviation difference between the end of the first treatment and at baseline before the second treatment (in those who received it) was 2 ± 2 for CAS, 2 ± 4 mm for proptosis, and 1 ± 1 for diplopia score. Age was the only significant driver of re-treatment ( < 0.05). Re-treated patients were 7 years older than patients who were not re-treated (60 years vs. 53 years; < 0.05). In patients receiving a full course of teprotumumab therapy, the rate of re-treatment was 24%. Age was the only driver of re-treatment. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

中文翻译：

---

接受 Teprotumumab 治疗的患者的再治疗率：一项对 119 名患者进行 1 年随访的多中心研究


旨在确定接受全程替普罗妥尤单抗治疗甲状腺眼病 (TED) 的患者的再治疗率以及再治疗的驱动因素。多中心回顾性研究。所有接受完整疗程治疗并在初始治疗后 1 年后有可用数据的患者均被纳入。图表中包含以下信息：年龄、性别、自诊断出 TED 以来的月数、吸烟状况和既往治疗情况。此外，在基线、第一个疗程结束时以及第二个疗程的基线时，对接受治疗的患者的临床活动评分 (CAS)、突眼和 Gorman 复视评分进行了审查。创建逻辑回归模型来审查再治疗的驱动因素。再治疗率和再治疗的驱动因素。来自美国 3 个中心的 119 名患者被纳入其中。总体再治疗率为 24% (29/119)。 3 个站点之间没有发现差异 (= 0.6)。在单变量分析中，基线时，接受再治疗和未接受再治疗的患者之间的突眼 (= 0.07)、复视评分 (= 0.4) 或 TED 持续时间 (= 0.4) 没有差异。在重新治疗组中，82% 的患者在初始疗程后表现出显着的眼球突出反应（较基线减少≥ 2 毫米），而未重新治疗的患者中有 68% 表现出临床显着的眼球突出反应 (= 0.16)。第一次治疗结束时与第二次治疗前基线（接受治疗的患者）之间的平均值±标准差差异，CAS 为 2 ± 2，突眼评分为 2 ± 4 mm，复视评分为 1 ± 1。年龄是再治疗的唯一重要驱动因素 (< 0.05)。接受再治疗的患者比未接受再治疗的患者年长 7 岁（60 岁 vs 60 岁）。 53岁； < 0.05)。在接受完整疗程替普罗妥尤单抗治疗的患者中，再治疗率为 24%。年龄是重新治疗的唯一驱动因素。专有或商业披露可在本文末尾的脚注和披露中找到。